Cognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer's Disease Processes

Core Insights - Cognition Therapeutics, Inc. presented biomarker results from the Phase 2 SHINE study of zervimesine (CT1812) for mild-to-moderate Alzheimer's disease at the AD/PD 2025 Conference [1][2] Group 1: Study Findings - The study analyzed changes in biomarkers, particularly focusing on participants with lower levels of p-Tau217, a protein indicative of Alzheimer's pathology [2][3] - Participants treated with zervimesine showed reductions in plasma biomarkers associated with Alzheimer's compared to placebo, with the low-p-Tau217 subgroup experiencing more pronounced reductions [3][4] - Significant reductions were noted in glial fibrillary acidic protein (GFAP) and neurofilament light (NfL), both associated with neuroinflammation and neurodegeneration, respectively [4][5] Group 2: Presentation Details - The presentation titled "Positive Impact of CT1812 Treatment on Plasma Biomarkers in Lower p-tau217 Subgroup Aligns with Clinical Benefits in Mild-to-Moderate AD Patients" was delivered by Dr. Mary Hamby on April 1, 2025 [5] - Additional presentations included analyses of CSF proteomic biomarkers and molecular correlates related to cognitive outcomes in participants of the SHINE study [5] Group 3: Company Overview - Cognition Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutics for age-related neurodegenerative disorders, with zervimesine being the lead candidate [6] - The company is also investigating zervimesine in other clinical programs, including dementia with Lewy bodies [6]